ClinicalTrials.gg
CompletedNCT04451330DUALUpdated May 10, 2022Results posted

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

A Phase 4 interventional study of Trifarotene cream and Doxycycline hyclate in Acne Vulgaris, sponsored by Galderma R&D. Completed at 26 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-05-10.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
9th of 12
202 · median 507
Started
2020
the only one that year
Phase 4
3 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 9th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 4, and was the 6th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

The purpose of this study was to demonstrate that daily use of topical trifarotene (CD5789) 50 microgram per gram (mcg/g) cream when used in association with oral antibiotic is safe and effective for the treatment of severe AV.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with clinical diagnosis of acne vulgaris, defined by IGA score of 4 (Severe)
  • Participants with at least 20 inflammatory lesions (papules and pustules) and 30 to 120 non-inflammatory lesions (open comedones and closed comedones) and no more than 2 nodules (less than [\<]1 centimeter [cm] in diameter) on the face, excluding the nose
  • Agrees to provide written
  • Participant is a female of non- (premenarchal or [absence of menstrual bleeding for 1 year prior to Screening, without any other medical reason], hysterectomy or bilateral oophorectomy)

Exclusion criteria

Exclusion Criteria:

  • Participant with any acne cyst on the face
  • Participants with nodulocystic or conglobate acne, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc.)
  • Participants with facial dermal conditions (example [e.g.] tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator
  • Participants who is at risk in terms of precautions, warnings, and for trifarotene or doxycycline hyclate
  • Currently receiving any prescription testosterone therapy (e.g., testosterone cypionate, testosterone enanthate, testosterone pellet, testosterone undecanoate) or on a testosterone booster or prescription testosterone (e.g., dehydroepiandrosterone [DHEA], Omnadren, Sustanon, testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone phenylpropionate) or testosterone supplements (e.g., Tribulus).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Trifarotene Cream + Doxycycline

    Participants were applied with Trifarotene (CD5789) 50 micrograms per gram (mcg/g) cream topically on the face once daily in the evening for 12 weeks and received doxycycline 120 milligrams (mg) tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.

    Drug: Trifarotene cream · Drug: Doxycycline hyclate

  • Placebo comparator
    Trifarotene Vehicle + Doxycycline Placebo

    Participants were applied with vehicle CD5789 topically on the face once daily in the evening for 12 weeks and received doxycycline matching placebo tablet orally once daily in the evening and 1 tablet in the morning on Day 2 of every week for 12 weeks.

    Drug: Trifarotene Vehicle · Drug: Doxycycline Placebo

Interventions

  • Trifarotene 50 mcg/g cream applied topically once daily on face for 12 weeks.

    Also known as: AKLIEF

  • Doxycycline hyclate delayed release 120 mg tablets was administered orally for 12 weeks.

    Also known as: DORYX MPC

  • DrugTrifarotene Vehicle

    Trifarotene 50 mcg/g vehicle cream was applied topically once daily on face for 12 weeks.

  • DrugDoxycycline Placebo

    Doxycycline hyclate delayed release 120 mg placebo tablets was administered orally for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Facial Total Lesion Counts to Week 12

    Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedos; diagnosis based on palpation) on the face.

    Time frame: From Baseline to Week 12

Secondary outcomes

  1. Absolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12

    All inflammatory lesions (papules, pustules, and nodular lesions) were counted by investigator/subinvestigator.

    Time frame: From Baseline to Week 12

  2. Absolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12

    Non-inflammatory lesions (open and closed comedo) were counted by investigator/subinvestigator.

    Time frame: From Baseline to Week 12

  3. Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12

    IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

    Time frame: From Baseline to Week 12

07

Results

Posted May 10, 2022

Participant flow

Study was conducted at United States of America and Puerto Rico between 29 Jul 2020 and 26 Apr 2021.

Participant flow — Overall Study
MilestoneTrifarotene (CD5789) Cream + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Started13369
Completed12365
Not completed104
Withdrew: Adverse event12
Withdrew: Lost to follow-up50
Withdrew: Withdrawal by subject31
Withdrew: Withdrawal by parent/guardian10
Withdrew: Other than specified01

Outcome measures

PrimaryAbsolute Change From Baseline in Facial Total Lesion Counts to Week 12

Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules. The investigator (or subinvestigator) counted all inflammatory lesions (papules, pustules, and nodular lesions) and non-inflammatory lesions (open and closed comedos; diagnosis based on palpation) on the face.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · Lesion counts
Absolute Change From Baseline in Facial Total Lesion Counts to Week 12
Lesion countsTrifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Absolute Change From Baseline in Facial Total Lesion Counts to Week 12-69.1 ± 2.28-48.1 ± 3.14
SecondaryAbsolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12

All inflammatory lesions (papules, pustules, and nodular lesions) were counted by investigator/subinvestigator.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · Lesion counts
Absolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12
Lesion countsTrifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Absolute Change From Baseline in Facial Inflammatory Lesions (IL) Counts to Week 12-29.4 ± 1.09-19.5 ± 1.49
SecondaryAbsolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12

Non-inflammatory lesions (open and closed comedo) were counted by investigator/subinvestigator.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · Lesion counts
Absolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12
Lesion countsTrifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Absolute Change From Baseline in Facial Non Inflammatory Lesions (NIL) Counts to Week 12-39.5 ± 1.42-28.2 ± 1.96
SecondaryPercentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12

IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

Time frame:
From Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12
percentage of participantsTrifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 1231.715.8

Adverse events

Collected over From Baseline up to Week 12.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifarotene + Doxycycline0/133 (0%)1/133 (0.8%)0/133 (0%)
Trifarotene Vehicle + Doxycycline Placebo0/69 (0%)0/69 (0%)0/69 (0%)
Most frequent serious events
Most frequent serious events
EventTrifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline Placebo
Self-Injurious IdeationPsychiatric disorders1/1330/69

Baseline characteristics

Analysis was performed on Intent to treat (ITT) population that included all participants who were randomized.

Age, Continuous
Age, Continuous(years)Trifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline PlaceboTotal
Mean20.0 ± 7.3020.3 ± 8.9220.1 ± 7.87
Sex: Female, Male
Sex: Female, Male(Participants)Trifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline PlaceboTotal
Female8043123
Male532679
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline PlaceboTotal
Hispanic or Latino502070
Not Hispanic or Latino8349132
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline PlaceboTotal
American Indian or Alaska Native000
Asian639
Native Hawaiian or Other Pacific Islander101
Black or African American9615
White11458172
More than one race325
Unknown or Not Reported000
Facial Total Lesions Counts
Facial Total Lesions Counts(Lesion counts)Trifarotene + DoxycyclineTrifarotene Vehicle + Doxycycline PlaceboTotal
Mean101.5 ± 40.11100.7 ± 33.91101.2 ± 38.02
08

Study locations

26 sites
  • Galderma Investigational Site
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site
    Hot Springs, Arkansas 71913, United States
  • Galderma Investigational Site
    Rogers, Arkansas 72758, United States
  • Galderma Investigational Site
    Newport Beach, California 92663, United States
  • Galderma Investigational Site
    Aventura, Florida 33180, United States
  • Galderma Investigational Site
    Boca Raton, Florida 33486, United States
  • Galderma Investigational Site
    Miramar, Florida 33027, United States
  • Galderma Investigational Site
    Newnan, Georgia 30263, United States
  • Galderma Investigational Site
    Evansville, Indiana 47715, United States
  • Galderma Investigational Site
    New Albany, Indiana 47150, United States
  • Galderma Investigational Site
    Rockville, Maryland 20850, United States
  • Galderma Investigational Site
    Warren, Michigan 48088, United States
  • Galderma Investigational Site
    New Brighton, Minnesota 55112, United States
  • Galderma Investigational Site
    Las Vegas, Nevada 89148, United States
  • Galderma Investigational Site
    Stony Brook, New York 11790, United States
  • Galderma Investigational Site
    High Point, North Carolina 27262, United States
  • Galderma Investigational Site
    Sugarloaf, Pennsylvania 18249, United States
  • Galderma Investigational Site
    Charleston, South Carolina 71913, United States
  • Galderma Investigational Site
    Knoxville, Tennessee 37922, United States
  • Galderma Investigational Site
    Arlington, Texas 76011, United States
  • Galderma Investigational Site
    Dallas, Texas 75246, United States
  • Galderma Investigational Site
    Grapevine, Texas 76051, United States
  • Galderma Investigational Site
    Pflugerville, Texas 78660, United States
  • Galderma Investigational Site
    San Antonio, Texas 78218, United States
  • Galderma Investigational Site
    San Antonio, Texas 78249, United States
  • Galderma Investigational Site
    Aibonito, 705, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Apr 2021, 8 months.

Results were first posted in May 2022, 1 year after primary completion.

Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2020
First posted
Jun 30, 2020
StartActual
Jul 29, 2020
Primary completionActual
Apr 26, 2021
CompletionActual
Apr 26, 2021
Results first posted
May 10, 2022
Last update
May 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04451330
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 29, 2020
Primary completion
Apr 26, 2021
Completion
Apr 26, 2021
Results posted
May 10, 2022
Last update
May 10, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion